RELMADA THERAPEUTICS INC (RLMD) Stock Income Statement
NASDAQ:RLMD - US75955J4022 - Common Stock
1.12 USD
+0.35 (+44.52%)
1.0417 USD
-0.08 (-6.99%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 70.00M | 84.00M | 104.00M | 161.25M | 125.70M | |||
| Research and Development | N/A | 46.18M | 54.81M | 113.32M | 90.62M | |||
| Selling, General, and Administrative Expenses | 33.75M | 38.00M | 49.00M | 47.93M | 35.08M | |||
| Operating Income | -70.00M | -84.00M | -104.00M | -161.25M | -125.70M | |||
| Interest Income/Expense | N/A | 3.91M | 4.91M | -2.15M | -50.00K | |||
| Other Income/Expense | N/A | N/A | 0.00 | 6.35M | N/A | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -68.87M | -80.00M | -99.00M | -157.04M | -125.75M | |||
| Income Tax | N/A | N/A | N/A | N/A | N/A | |||
| Net Income | -68.87M | -80.00M | -99.00M | -157.04M | -125.75M | |||
| EBITDA | N/A | N/A | N/A | N/A | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.24 | -2.65 | -3.30 | -5.30 | -7.16 | |||
| Non GAAP EPS | -2.22 | -2.65 | -3.28 | -5.45 | -7.14 | |||
| Statistics | ||||||||
All data in USD